The uterus consists of the corpus (body) and cervix. Although cervical and endometrial (i.e. corpus) carcinomas arise at adjacent anatomic sites in the same organ and have a common embryologic origin in the Mllerian epithelium, cervical and endometrial carcinomas have very different biological and clinical features. Endometrial cancer is the most common cancer of the female reproductive tract, and its incidence is rapidly growing due to the increase in obesity, a significant risk factor. Cervical cancer, among the most common cancers worldwide, is caused by infection with HPV, followed by the acquisition of oncogenic mutations that drive tumor progression. Studies from our laboratory and others have recently shown that inactivation of the LKB1 tumor suppressor by diverse mechanisms is a common and key driving event shared by both types of uterine cancer. LKB1 inactivation promotes tumor progression in part through its control of metabolism via the AMPK/mTOR signaling axis, but this process alone cannot fully account for all of the biological effects of LKB1, such as the strong association between LKB1 inactivation and invasion, metastasis, and a poor clinical outcome. Our extensive preliminary data-based on genetically-engineered mouse models and human cell line studies-has revealed that tumor inflammation is a novel but nonetheless essential pro-tumorigenic process triggered by LKB1 loss. Here, we propose to study this heretofore unexplored aspect of LKB1's actions as a tumor suppressor through a diverse but complementary set of cell line models, genetically-engineered mice, and translational studies employing human tumor specimens. Our laboratory has extensive experience in these mouse and cell line models, which we have already developed, and also in biomarker development and the analysis of human tumor specimens. This project will also benefit from our collaborators' collective expertise in LKB1, tumor-host interactions, and cell migration. This work could have far-reaching implications for our understanding of LKB1-driven cancers and lead to better treatments against these highly-lethal malignancies.

Public Health Relevance

Genetic inactivation of the LKB1 tumor suppressor is a common, signature molecular lesion that occurs across many different types of common and incurable malignancies including lung cancer, uterine cancer, skin cancer, and pancreatic cancer. This program project seeks to understand the novel biological actions of LKB1 through the chemokine CCL2 and how these actions synergize in driving tumor initiation and spread in different types of cancers of the uterus. The goal is to gain a sufficient understanding of LKB1 biology to inform the development and implementation of effective therapeutic combinations that will specifically target tumors characterized by LKB1 loss.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA196912-03
Application #
9456675
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2016-04-01
Project End
2021-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pathology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Strickland, Amanda L; Rivera, Glorimar; Lucas, Elena et al. (2018) PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia. Int J Gynecol Pathol :
Kim, Jiyeon; Hu, Zeping; Cai, Ling et al. (2017) CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature 546:168-172
Aguilera, Kristina Y; Huang, Huocong; Du, Wenting et al. (2017) Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 16:2473-2485
Peña, Christopher G; Castrillón, Diego H (2017) LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies. Adv Exp Med Biol 943:211-241
Thu, Kelsie L; Papari-Zareei, Mahboubeh; Stastny, Victor et al. (2016) A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget :
Peña, Christopher G; Nakada, Yuji; Saatcioglu, Hatice D et al. (2015) LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest 125:4063-76